Abstract:1. Clinical investigations at the University of Cincinnati have focused primarily on infection control, methods to increase donor-specific unresponsiveness, improvement in immunosuppression, donor maintenance and evaluation, posttransplant monitoring, and reduced-size livers for children. 2. Donor specific unresponsiveness (DSU) can be achieved frequently in recipients of both cadaver donor and living related donor kidneys by giving a single donor specific transfusion and CsA only 24 hours preoperatively with continuing triple immunosuppressive therapy. 3. Prednisone can be withdrawn from almost all patients with no rejection by 1 year with significant improvement in blood pressure, daily insulin requirement in diabetics, total blood cholesterol, and low density lipoproteins (LDL). 4. Oral ketoconazole 200 mg/day can be used safely to block the hepatic metabolism of CsA and reduce the amount of CsA administered by an average of 77-88%. This is of great economic consequence to lower income patients and patients with poor drug absorption. 5. Eighteen patients with SLE who received 23 kidney transplantations had an increase in graft loss in the first 6 months but the rate of graft loss after 6 months was almost identical to other ESRD patients. 6. The Cincinnati Transplant Tumor Registry has data on about 8,000 patients. Except for those with CNS tumors, patients with active cancers should not be used as donors. However, donors with previous curative procedures should not be excluded automatically. Cancers arising in immunosuppressed transplant recipients that have a higher incidence than the general population (expressed as percentage of treated cancers) are: lymphomas (22% vs 5%), lip cancers (7% vs 0.3%), Kaposi's sarcoma (6% vs less than 0.1%), vulva and perineal cancers (4% vs 0.6%), hepatobiliary cancers (2.5% vs 1.0%) and sarcomas (1.8% vs 0.5%). Other cancers have about the same-distribution. 7. Immunologic monitoring during OKT3 therapy is particularly useful in re-treatment and treatment of pediatric liver patients when increased doses of the drug may be necessary. 8. The MEGX test has been found to be a major predictor of primary non-function of the transplanted liver, and it is also useful in predicting the risks of dying from liver disease. 9. Reduced-size livers have been used in 37 patients, representing almost half of all pediatric liver transplants. Survival with reduced-size grafts (91% at 1 year) compared favorably with survival of whole organs (79% at 1 year). The benefit is particularly dramatic in infants with biliary atresia (100% 1-year graft survival in 24 patients, median age 11 months).(ABSTRACT TRUNCATED AT 400 WORDS)

Relative risk of donor‐transmitted Toxoplasma gondii infection in heart, liver and kidney transplant recipients

Pre-Transplant Seroprevalence, Associated Factors, and Post-Transplant Incidence of Toxoplasma gondii Infection Among Heart Transplant Recipients in Japan

Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients

Issues of Immunological and Hemodynamic Monitoring Before and During Kidney Transplantation in Sensitized Heart Transplant Recipient

The impact of donor hepatitis B virus infection on transplant outcomes in deceased donor kidney transplantation recipients

Analysis of Correlative Factors in Infection of Liver Transplant Recipients.

Chronological and Geographical Variations in the Incidence and Acceptance of COVID-19-Positive Donors and Outcomes Among Abdominal Transplant Patients

Incidence, Distribution and Clinical Relevance of Microbial Contamination of Preservation Solution in Deceased Kidney Transplant Recipients: a Retrospective Cohort Study from China.

Impact of Donor Diabetes Mellitus Status on Liver Transplant Outcomes in Patients with Acute-on-chronic Liver Failure

Non-Standard Risk Donors and Risk of Donor-Derived Infections: From Evaluation to Therapeutic Management

The Influence of Infection of Hepatitis B and Hepatitis C Virus on the Long-Term Survival of the Renal Transplantation Recipients

Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis

Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis

Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety

Presensitization and kidney transplant failures

Hepatitis B in Heart Transplant Donors and Recipients: A Systematic Review and Meta-Analysis

Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement

Microbial Epidemiology and Risk Factors of Infections in Recipients after DCD Liver Transplantation

Impact of donor multidrug‐resistant organisms on solid organ transplant recipient outcomes

Recent contributions to transplantation at the University of Cincinnati

Parasitic infections in transplant recipients